SANYO North America Corp.’s
Biomedical Solutions Division and BD Biosciences, a segment of Becton, Dickinson and Co., last month announced a strategic agreement to jointly promote
cutting-edge life science research tools designed to advance cell culture and cell therapy research.
Proteome Sciences PLC, a global leader in applied proteomics and peptidomics, has entered into a collaboration agreement
with the renowned Moffitt Cancer Center to develop mass spectrometry assays measuring certain key signaling and repair pathway proteins that can be adapted
for tumor biopsy analysis in the clinic.
Harvard Bioscience Inc., a global developer of tools for life science research and regenerative medicine, announced last month that it has
acquired the preclinical business unit of CMA Microdialysis AB through a purchase of assets.
Isn’t it about time Congress revisited what is
essentially an afterthought on a 15-year-old appropriations bill, clearly articulated the facts and concerns about hESC research and put forth a specific
policy on the matter?